11.05
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Polyrizon
Its shares trade under the ticker PLRZ. It has been listed since 29 October 2024.
Polyrizon Ltd is a IL-based company operating in Biotechnology industry. Polyrizon Ltd is an Israel-based biotechnology company. The firm is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The firm is focused not only on the development of intranasal products, but also on commercialization. The firm cooperates with medical specialists and researchers..
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Oct 2024
- Employees
- 1
- Website
- polyrizon-biotech.com ↗
- Head office
- HAPNINA ST 8, RA'ANANA, 4321545
- Incorporated in
- L3
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Tomer IzraeliChief Executive Officer, Director, since 2005$298,000
- Mr. Nir Ben YosefChief Financial Officer$138,000
- Ms. Daphna AvitalChief People Officer
- Dr. Tidhar TurgemanChief Technology Officer$184,000
- Dr. Eyal RonChief Science Officer$2,000
- Mr. Oz AdlerDirector
- Mr. Liron CarmelDirector
- Mr. Asaf ItzhaikIndependent Director
- Ms. Liat SidiIndependent Director
- Mr. Omer SrugoIndependent Director
- Mr. Yehonatan VinokurIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Polyrizon Ltd's nasal spray hydrogels provide a natural barrier against viruses and allergens in the nasal cavity.
- The company focuses on both development and commercialization of intranasal medical devices.
- Collaboration with medical specialists and researchers enhances product efficacy and innovation.
Weaknesses
- Polyrizon Ltd has only one employee, limiting operational capacity and scalability.
- The company is listed on 29 October 2024, indicating a very recent market entry.
- Israel-based operations may face challenges in global market penetration and distribution.
Opportunities
- Growing demand for nasal barrier products in the Health Care sector globally.
- Potential expansion into the Biotechnology industry with new hydrogel applications.
- Partnerships with medical institutions in Israel could drive further innovation.
Threats
- Competition from established biotechnology firms in the Health Care industry.
- Regulatory hurdles in the Biotechnology sector may delay product approvals.
- Economic instability in Israel could impact funding and market access.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.